Head-to-head · WeighScore
HealthRX vs Klinic
The verdict
HealthRX takes it — 86.1/100 to 60.8/100.
HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified (#50087439) physician-supervised program that runs a rare oral GLP tablet alongside the usual injectables — compounded semaglutide from ~$189/mo, tirzepatide/GLP+GIP up to ~$349, with a brand Ozempic pass-through if you need it.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | HealthRX | Klinic |
|---|---|---|
| WeighScore | 86.1/100 | 60.8/100 |
| Grade | B | C |
| Scorecard rank | #8 | #312 |
| Semaglutide | $189/mo | Not disclosed |
| Tirzepatide | $349/mo | Not disclosed |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #8 · B
Strengths
- LegitScript-certified (#50087439) — a genuine, verifiable trust signal
- Physician-supervised intake with licensed providers
- Both molecules plus a rare oral GLP tablet option
- Transparent flat monthly pricing, no insurance required
Where it loses points
- Compounded semaglutide/tirzepatide is not FDA-approved
- Some tiers are company-stated and the public site is thin
- Brand Ozempic is a steep pass-through (~$1,299)
- State count is not publicly listed
Graded #312 · C
Strengths
- LegitScript certified, licensed in all 50 states, DEA registered, HIPAA/SOC 2 Type II compliant
- Broad insurance acceptance including Medicare, Medicaid, BCBS, Aetna, Cigna, UHC, and Humana
- Klinic handles all prior authorization—patient never manages PA paperwork
- Brand-name FDA-approved GLP-1s (Wegovy, Zepbound) at full clinical doses with home delivery
- Named clinical leadership (CMO Dr. Saba Haq, Chief Physician Dr. Vivek Chander) and disclosed founder
Where it loses points
- Brand-name meds are costly self-pay: Wegovy ~$499/month, Zepbound ~$299/month (med cost alone; consult extra)
- No compounded semaglutide or tirzepatide option for patients seeking lower-cost alternatives
- Medication cost is separate from visit fees ($99 initial, $75 follow-up) — total self-pay cost is higher
- No labs or dedicated nutrition/coaching program included in any plan
- Pharmacy fulfillment via Klinic Pharmacy Hub Services LLC (non-dispensing hub); actual dispensing is third-party
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.